Outcomes in unrelated donor BMT recipients with and without KIR ligand incompatibility
| End points . | All diagnoses (N = 175) . | Myeloid malignancy (n = 72) . | ||||
|---|---|---|---|---|---|---|
| No KIR ligand incompatibility, n = 113 % (95% CI) . | KIR ligand incompatibility, n = 62 % (95% CI) . | P . | No KIR ligand incompatibility, n = 48 % (95% CI) . | KIR ligand incompatibility, n = 24 % (95% CI) . | P . | |
| Graft failure | 7 (2-12) | 8 (3-13) | .81 | 8 (0-16) | 13 (28-39) | .57 |
| Grades II-IV GVHD | 50 (40-60) | 61 (47-75) | .09 | 56 (40-72) | 67 (56-88) | .28 |
| Grades III-IV GVHD | 23 (15-31) | 26 (15-37) | .71 | 25 (13-37) | 38 (19-57) | .24 |
| Relapse at 5 y | 12 (6-18) | 9 (2-16) | .51 | 19 (8-30) | 13 (1-25) | .97 |
| Survival | ||||||
| 1 y | 50 (41-59) | 47 (35-59) | .32 | 54 (37-68) | 29 (11-47) | < .01 |
| 5 y | 40 (31-49) | 32 (20-44) | 38 (24-52) | 13 (0-26) | ||
| End points . | All diagnoses (N = 175) . | Myeloid malignancy (n = 72) . | ||||
|---|---|---|---|---|---|---|
| No KIR ligand incompatibility, n = 113 % (95% CI) . | KIR ligand incompatibility, n = 62 % (95% CI) . | P . | No KIR ligand incompatibility, n = 48 % (95% CI) . | KIR ligand incompatibility, n = 24 % (95% CI) . | P . | |
| Graft failure | 7 (2-12) | 8 (3-13) | .81 | 8 (0-16) | 13 (28-39) | .57 |
| Grades II-IV GVHD | 50 (40-60) | 61 (47-75) | .09 | 56 (40-72) | 67 (56-88) | .28 |
| Grades III-IV GVHD | 23 (15-31) | 26 (15-37) | .71 | 25 (13-37) | 38 (19-57) | .24 |
| Relapse at 5 y | 12 (6-18) | 9 (2-16) | .51 | 19 (8-30) | 13 (1-25) | .97 |
| Survival | ||||||
| 1 y | 50 (41-59) | 47 (35-59) | .32 | 54 (37-68) | 29 (11-47) | < .01 |
| 5 y | 40 (31-49) | 32 (20-44) | 38 (24-52) | 13 (0-26) | ||